Abstract
Studies on hypoxia-signaling pathways have revealed novel Fe(II) and α-ketoglutarate-dependent dioxygenases that hydroxylate prolyl or asparaginyl residues of a transactivator, Hypoxia-Inducible Factor-α (HIF-α) protein. The recognition of these unprecedented dioxygenases has led to open a new paradigm that the hydroxylation mediates an instant post-translational modification of a protein in response to the changes in cellular concentrations of oxygen, reducing agents, or α-ketoglutarate. Activity of HIF-α is repressed by two hydroxylases. One is HIF-α specific prolyl-hydroxylases, referred as prolyl-hydroxylase domain (PHD). The other is HIF-α specific asparaginyl-hydroxylase, referred as factor-inhibiting HIF-1 (FIH-1). The facts (i) that many dioxygenases commonly use molecular oxygen and reducing agents during detoxification of xenobiotics, (ii) that detoxification reaction produces radicals and reactive oxygen species, and (iii) that activities of both PHD and FIH-1 are regulated by the changes in the balance between oxygen species and reducing agents, imply the possibility that the activity of HIF-α can be increased during detoxification process. The importance of HIF-α in cancer and ischemic diseases has been emphasized since its target genes mediate various hypoxic responses including angiogenesis, erythropoiesis, glycolysis, pH balance, metastasis, invasion and cell survival. Therefore, activators of PHDs and FIH-1 can be potential anticancer drugs which could reduce the activity of HIF, whereas inhibitors, for preventing ischemic diseases. This review highlights these novel dioxygenases, PHDs and FIH-1 as specific target against not only cancers but also ischemic diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baranova, O., Miranda, L.F., Pichiule, P., Dragatsis, I., Johnson, R.S. and Chavez, J.C. (2007). Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci., 27, 6320–6332.
Berra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D. and Pouysségur, J. (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J., 22, 4082–4090.
Brahimi-Horn, M.C. and Pouysségur, J. (2007). Oxygen, a source of life and stress. FEBS Lett, 581, 3582–3591.
Brüne, B. and Zhou, J. (2007). Nitric oxide and superoxide: Interference with hypoxic signaling. Cardiovasc Res., 75, 275–282.
Choi, K.O., Lee, T., Lee, N., Kim, J.H., Yang, E.G., Yoon, J.M., Kim, J.H., Lee, T.G. and Park, H. (2005). Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYND-type zinc finger. Mol. Pharmacol., 68, 1803–1809.
Choi, H.J., Song, B.J., Gong, Y.D., Gwak, W.J. and Soh, Y. (2008). Rapid degradation of hypoxia-inducible factor-1 alpha by KRH102053, a new activator of prolyl hydroxylase 2. Br. J. Pharmacol., 154, 114–125.
Choi, S.M., Choi, K.O., Park, Y.K., Cho, H., Yang, E.G. and Park, H. (2006). Clioquinol, a Cu(ll)/Zn(ll) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1 alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells. J. Biol. Chem., 281, 34056–34063.
Cockman, M.E., Lancaster, D.E., Stolze, I.P., Hewitson, K.S., McDonough, M.A., Coleman, M.L., Coles, C.H., Yu, X., Hay, R.T., Ley, S.C., Pugh, C.W., Oldham, N.J., Masson, N., Schofield, C.J. and Ratcliffe, P.J. (2006). Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc. Natl. Acad. Sci. USA, 103, 14767–14772.
Crews, S.T. (1998). Control of cell lineage-specific development and transcription by bHLH-PAS proteins. Genes Dev., 12, 607–620.
Epstein, A.C., Gleadle, J.M., McNeill, L.A., Hewitson, K.S., O’Rourke, J., Mole, D.R., Mukherji, M., Metzen, E., Wilson, M.I., Dhanda, A., Tian, Y.M., Masson, N., Hamilton, D.L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P.H., Pugh, C.W., Schofield, C.J. and Ratcliffe, P.J. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107, 43–54.
Esteban, M.A. and Maxwell, P.H. (2005). HIF, a missing link between metabolism and cancer. Nat. Med., 10, 1047–1048.
Esteban, M.A., Tran, M.G., Harten, S.K., Hill, P., Castellanos, M.C., Chandra, A., Raval, R., O’brien, T.S. and Maxwell, P.H. (2006). Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res., 66, 3567–3575.
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z.M., Felsher, D.W., Cheng, L., Pevsner, J., Lee, L.A., Semenza, G.L. and Dang, C.V. (2007). HIF-depen-dent antitumorigenic effect of antioxidants in vivo. Cancer Cell, 12, 230–238.
Grimm, C., Wenzel, A., Groszer, M., Mayser, H., Seeliger, M., Samardzija, M., Bauer, C., Gassmann, M. and Remé, C.E. (2002). HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med., 8, 718–724.
Ginouvès, A., Ilc, K., Macías, N., Pouysségur, J. and Berra, E. (2008). PHDs overactivation during chronic hypoxia “desensitizes” HIF alpha and protects cells from necrosis. Proc. Natl. Acad. Sci. USA, 105, 4745–4750.
Hewitson, K.S., McNeill, L.A., Riordan, M.V., Tian, Y.M., Bullock, A.N., Welford, R.W., Elkins, J.M., Oldham, N.J., Bhattacharya, S., Gleadle, J.M., Ratcliffe, P.J., Pugh, C.W. and Schofield, C.J. (2002). Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem., 277, 26351–26355.
Hewitson, K.S., Lienard, B.M., McDonough, M.A., Clifton, I.J., Butler, D., Soares, A.S., Oldham, N.J., McNeill, L.A. and Schofield, C.J. (2007). Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J. Biol. Chem., 282, 3293–3301.
Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K.I. and Myllyharju, J. (2003). Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem., 278, 30772–30780.
Hirsilä, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K.I. and Myllyharju, J. (2005). Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J., 19, 1308–1310.
Holmquist-Mengelbier, L., Fredlund, E., Lofstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, A., Gradin, K., Poellinger, L. and Pahlman, S. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell, 10, 413–423.
Isaacs, J.S., Jung, Y.J., Mole, D.R., Lee, S., Torres-Cabala, C., Chung, Y.L., Merino, M., Trepel, J., Zbar, B., Tora, J., Ratcliffe, P.J., Linehan, W.M. and Neckers, L. (2005). HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell, 8, 143–153.
Jewell, U.R., Kvietikova, I., Scheid, A., Bauer, C., Wenger, R.H. and Gassmann, M. (2001). Induction of HIF-1 alpha in response to hypoxia is instantaneous. FASEB J., 15, 1312–1314.
Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G.L. and Hirota, K. (2004). Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem., 279, 2550–2558.
Koike, T., Kimura, N., Miyazaki, K., Yabuta, T., Kumamoto, K., Takenoshita, S., Chen, J., Kobayashi, M., Hosokawa, M., Taniguchi, A., Kojima, T., Ishida, N., Kawakita, M., Yamamoto, H., Takematsu, H., Suzuki, A., Kozutsumi, Y. and Kannagi, R. (2004). Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc. Natl. Acad. Sci. USA, 101, 8132–8137.
Klose, R.J., Kallin, E.M. and Zhang, Y. (2006). JmjC-domain-containing proteins and histone demethylation. Nat. Rev. Genet., 7, 715–727.
Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K.I. and Myllyharju, J. (2004). Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem., 279, 9899–9904.
Koivunen, P., Hirsilä, M., Remes, A.M., Hassinen, I.E, Kivirikko, K.I. and Myllyharju, J. (2007). Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem., 282, 4524–4532.
Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L. and Bruick, R.K. (2002). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev., 16, 1466–1471.
Li, F., Sonveaux, P., Rabbani, Z.N., Liu, S., Yan, B., Huang, Q., Vujaskovic, Z., Dewhirst, M.W. and Li, C.Y. (2007). Regulation of HIF-1 alpha stability through S-nitrosylation. Mol. Cell, 26, 63–74.
Lee, C., Kim, S.J., Jeong, D.G., Lee, S.M. and Ryu, S.E. (2003). Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J. Biol. Chem., 278, 7558–7563.
McNeill, L.A., Hewitson, K.S., Claridge, T.D., Seibel, J.F., Horsfall, L.E. and Schofield, C.J. (2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem. J., 367, 571–575.
Mahon, P.C., Hirota, K. and Semenza, G.L. (2001). FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev., 15, 2675–2686.
Masson, N., Willam, C., Maxwell, P.H., Pugh, C.W. and Ratcliffe, P.J. (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J., 20, 5197–5206.
Nangaku, M., Kojima, I., Tanaka, T., Ohse, T., Kato, H. and Fujita, T. (2006). Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase. Recent Patents Cardiovasc Drug Discov., 1, 129–139.
Natarajan, R., Salloum, F.N., Fisher, B.J., Kukreja, R.C. and Fowler, A.A. 3rd. (2006). Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ. Res., 98, 133–140.
Ng, S.S., Kavanagh, K.L., McDonough, M.A., Butler, D., Pilka, E.S., Lienard, B.M., Bray, J.E., Savitsky, P., Gileadi, O., von Delft, F., Rose, N.R., Offer, J., Scheinost, J.C., Borowski, T., Sundstrom, M., Schofield, C.J. and Oppermann, U. (2007). Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature, 448, 87–91.
Nytko, K.J., Spielmann, P., Camenisch, G., Wenger, R.H. and Stiehl, D.P. (2007). Regulated function of the prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins. Anti-oxid Redox Signal, 9, 1329–1338.
Park, Y.K., Ahn, D.R., Oh, M., Lee, T., Yang, E.G., Son, M. and Park, H. (2008). The nitric oxide donor, snap, stabilizes trans-active hypoxia-inducible factor-1α by inhibiting vhl recruitment and asparagine hydroxylation. Mol. Pharmacol. (in press)
Pollard, P.J., Briere, J.J., Alam, N.A., Barwell, J., Barclay, E., Wortham, N.C., Hunt, T., Jeffery, R., Seedhar, P., Barwell, J., Latif, F., Gleeson, M.J., Hodgson, S.V., Stamp, G.W., Tomlinson, I.P. and Maher, E.R. (2005). Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet, 14, 2231–2239.
Pouysségur, J., Dayan, F. and Mazure, N.M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 441, 437–443.
Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77–85.
Semenza, G.L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci. STKE, 2007, cm8.
Shin, D.H., Kim, J.H., Jung, Y.J., Kim, K.E., Jeong, J.M., Chun, Y.S. and Park, J.W. (2007). Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett., 255, 107–116.
Shin, D.H., Chun, Y.S. and Park, J.W. (2008). Response: Oxygen-dependent effect of bortezomib on FIH-mediated repression of HIF-1. Blood, 111, 5259–5261.
Tian, H., Hammer, R.E., Matsumoto, A.M., Russell, D.W. and McKnight, S.L. (1998). The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev., 12, 3320–3324.
Vuorela, A., Myllyharju, J., Nissi, R., Pihlajaniemi, T. and Kivirikko, K.I. (1997). Assembly of human prolyl 4-hydroxylase and type III collagen in the yeast pichia pastoris: formation of a stable enzyme tetramer requires coexpression with collagen and assembly of a stable collagen requires coexpression with prolyl 4-hydroxylase. EMBO J., 16, 6702–6712.
Zheng, X., Linke, S., Dias, J.M., Zheng, X., Gradin, K., Wallis, T.P., Hamilton, B.R., Gustafsson, M., Ruas, J.L., Wilkins, S., Bilton, R.L., Brismar, K., Whitelaw, M.L., Pereira, T., Gorman, J.J., Ericson, J., Peet, D.J., Lendahl, U. and Poellinger, L. (2008). Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc. Natl. Acad. Sci. USA, 105, 3368–3373.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Park, H. Novel Dioxygenases, HIF-α Specific Prolyl-hydroxylase and Asparanginyl-hydroxylase: O2 Switch for Cell Survival. Toxicol Res. 24, 101–107 (2008). https://doi.org/10.5487/TR.2008.24.2.101
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2008.24.2.101